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Adaptation of the Clinical Dementia Rating
Scale for adults with Down syndrome
Christina N. Lessov-Schlaggar1,2* , Olga L. del Rosario1,2, John C. Morris3,4, Beau M. Ances3,4,5,6,
Bradley L. Schlaggar7,8,9 and John N. Constantino1,2

Abstract
Background: Adults with Down syndrome (DS) are at increased risk for Alzheimer disease dementia, and there is a
pressing need for the development of assessment instruments that differentiate chronic cognitive impairment,
acute neuropsychiatric symptomatology, and dementia in this population of patients.
Methods: We adapted a widely used instrument, the Clinical Dementia Rating (CDR) Scale, which is a component
of the Uniform Data Set used by all federally funded Alzheimer Disease Centers for use in adults with DS, and
tested the instrument among 34 DS patients recruited from the community. The participants were assessed using
two versions of the modified CDR—a caregiver questionnaire and an in-person interview involving both the
caregiver and the DS adult. Assessment also included the Dementia Scale for Down Syndrome (DSDS) and the
Raven’s Progressive Matrices to estimate IQ.
Results: Both modified questionnaire and interview instruments captured a range of cognitive impairments, a
majority of which were found to be chronic when accounting for premorbid function. Two individuals in the
sample were strongly suspected to have early dementia, both of whom had elevated scores on the modified CDR
instruments. Among individuals rated as having no dementia based on the DSDS, about half showed subthreshold
impairments on the modified CDR instruments; there was substantial agreement between caregiver questionnaire
screening and in-person interview of caregivers and DS adults.
Conclusions: The modified questionnaire and interview instruments capture a range of impairment in DS adults,
including subthreshold symptomatology, and the instruments provide complementary information relevant to the
ascertainment of dementia in DS. Decline was seen across all cognitive domains and was generally positively related to
age and negatively related to IQ. Most importantly, adjusting instrument scores for chronic, premorbid impairment
drastically shifted the distribution toward lower (no impairment) scores.
Keywords: Down syndrome, Dementia, Premorbid ability, Cognitive decline, Cognitive impairment

Background
Alzheimer disease (AD) is the most common cause of dementia [1]. Because of the aging population worldwide,
AD is reaching epidemic proportions; in 2018, an estimated 5.5 million United States citizens age 65 and older
had AD, which is projected to grow to 13.8 million by the
middle of this century if no effective therapies are developed to prevent, slow, or stop the disease [2]. Down
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syndrome (DS) is the most commonly identified genetic
cause of cognitive impairment. Adults with DS have an increased risk for developing AD dementia owing to the trisomy of chromosome 21 where the amyloid precursor
protein (APP) gene is located leading to overexpression of
both APP mRNA and amyloid beta (Aβ) peptide [3]. Dementia is often identified earlier in adults with DS compared with the typical aging population, with estimates of
about 10% in DS adults in their 40s, about 30% in their
50s, and as high as 80% of DS adults in their 60s [3–5].
Cognitive and functional decline are the salient indicators of AD [2, 6]. DS adults have pre-existing and varying
levels of intellectual disability and cognitive impairment
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[7] making it difficult to assess change relative to a typical
level of functioning. In the DS population, assessment of
change in cognitive function must take into account baseline cognitive abilities [8, 9]. One of the first instruments
to be modified for use in DS was the Dementia Questionnaire for Persons with Mental Retardation (DMR [10, 11],
since renamed the Dementia Questionnaire for People
with Learning Disabilities (DLD)). Criticisms of the DMR/
DLD include lack of assessment of change from earlier
level of functioning, which results in significant floor effects, and use of different cutoff scores of increasing stringency for higher levels of intellectual disability, the latter
of which is not always known or possible to assess [12–
14].
The Dementia Scale for Down Syndrome (DSDS) [15]
is an informant interview specifically for use in DS. It
contains a total of 60 items scored as present, absent,
typical of the individual, or not applicable; 20 items assess early-stage dementia, 20 items assess middle stage
dementia, 15 items assess late-stage dementia, and 5
items assess very late-stage dementia [15]. The DSDS
was developed and standardized in a sample of adults
the majority of whom had severe to profound intellectual disability; hence, the most common criticism is that
it may not be sensitive enough to detect dementia in
higher functioning individuals [16, 17]. A counterargument to this criticism is that informants may not be able
to detect early dementia-related changes in such individuals [17].
The Cambridge Examination for Mental Disorders in
the Elderly (CAMDEX) [18] is an informant interview
developed for neuropsychiatric diagnosis in the elderly,
including dementia. It was modified for use in DS
(CAMDEX-DS) [19, 20]. The CAMDEX-DS consists of
approximately 150 questions that ask about functional
difficulties in different cognitive domains, whether such
difficulties represent a deterioration in function, and the
extent of the deterioration (slight or great) [20]. The
CAMDEX-DS has moderate to high inter-rater reliability, good predictive validity, and correlates with change
in independent cognitive tasks administered to DS adults
longitudinally [19].
The Dementia Screening Questionnaire for Individuals
with Intellectual Disabilities (DSQIID [12]) was more recently developed and is gaining wider use and popularity. The DSQIID focuses specifically on change in
function relative to a premorbid level; it is brief and easy
to complete by a single informant. It has been translated
into multiple languages including Chinese [21] and Italian [13], and along with the original English version, all
versions have good psychometric properties [12, 13, 21].
In addition to these advances, it would be desirable to
adapt clinical staging instruments that are widely utilized
in scientific and clinical work involving AD dementia in
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the broader population to afford comparability of assessment and staging for scientific and clinical efforts involving individuals with DS. Therefore, we adapted the
Clinical Dementia Rating scale (CDR [22]) for use in DS.
The CDR is a semi-structured clinical diagnostic interview that is an integral component of the Uniform Data
Set [23] that is used by all federally funded Alzheimer
Disease Centers (ADC) to determine the presence or absence of dementia for individuals being evaluated at
ADCs. The semi-structured interviews are administered
separately to an informant and then to the research participant or patient and focus on capturing intraindividual change from previous cognitive and functional
performance levels. An experienced clinician then synthesizes the information from the interview to determine
the presence or absence of dementia and, when present,
its severity [22]. A CDR score of 0 indicates cognitive
normality, whereas scores of 0.5, 1, 2, and 3 indicate very
mild, mild, moderate, and severe dementia, respectively.
The primary goal of this project was to determine
whether adaptations of the CDR for DS—by both interview and caregiver report—could reliably capture variation among DS patients when implementing new
adaptations of an established dementia rating scale.

Methods
Sample

In the first study phase, families with DS adults aged 18
years and older were recruited from the St. Louis ARC, a
non-profit organization that provides support and services for individuals with intellectual and developmental
disabilities in the St. Louis region. Potential participants
were recruited via letters sent to the families by St. Louis
ARC. A total of 189 letters were sent asking families to
contact the study. Forty families (21.2% response rate)
contacted study staff over the telephone regarding their
interest to participate. Verbal consent was obtained from
the caregiver over the telephone and he/she was then
sent the questionnaire version of the modified CDR instrument (CDR-QDS) by postal mail. All forty CDRQDS instruments that were mailed were received back
for evaluation.
In the second study phase, families who completed the
CDR-QDS were subsequently invited to come to the laboratory. Families who agreed to participate after verbal
explanation over the telephone of this study phase were
sent the informed consent document to their homes
prior to their laboratory appointment. At the time of the
appointment, study staff went over study procedures, answered any questions, and obtained signed informed
consent from the caregiver/legal guardian and signed ascent from the DS adult. A question as to whether the
DS adult knew why he/she is in the laboratory was asked
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to both the informant and the DS adult as part of the
interview process, to assess capacity.
The laboratory appointment involved administration
of (1) the modified interview format of the CDR (CDRIDS) to the informant and to the DS adult; (2) the Dementia Scale for Down Syndrome (DSDS) [15], for convergent validity against which scores on the modified
CDR-QDS and CDR-IDS instruments were to be compared. The DSDS informant interview is used as a
screening tool for dementia diagnosis in the multisite,
longitudinal Neurodegeneration in Aging Down Syndrome study (NiAD) [24, 25]. It has high inter-rater reliability [15], moderate to high specificity and sensitivity
compared with clinical dementia diagnosis using DSMIV [26] or ICD-10 criteria [27], it correlates positively
with DMR scores [16, 28, 29] and is related to worse
memory task performance [29, 30] and lower scores on
information and orientation questions [30]; and (3) the
Raven’s Colored Progressive Matrices task [31] administered to the DS adult to estimate intelligence quotient
(IQ). This task was chosen as a reasonable estimate of
IQ that would not be limited by speech impairment that
can be observed in DS adults.
Results from this study were not given to patient families. This study was approved by the Institutional Review Board at Washington University in St. Louis.
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month, then the decline score would be 1 (current score
2–best ever score 1).
In still other cases, we changed response categories;
for example, the original CDR question “Rate his/her
ability to cope with small sums of money (e.g., calculate
change, leave a small tip)” has response categories: No
Loss (0), Some Loss (1), and Severe Loss (2). We
substituted No Loss with Never Able (0) and Some Ability/No Loss (0) response categories and kept Some Loss
(1) and Severe Loss (2). A difference (i.e., adjusted) score
could not be calculated for questions with these response options since change relative to premorbid ability
was implicit in the response options.
CDR-QDS scores were generated for each of six functional domains of the CDR—memory, judgment and
problem solving, orientation, community affairs, home
and hobbies, and personal care—by summing over response categories of individual questions/items within
each domain. Higher scores reflected greater cognitive
decline. Cognitive domain scores were summed for a
total CDR-QDS summary score. Unlike the interview
instrument described below, we did not generate CDRQDS global scores because published rules for generating a global score [22] are based on interview data with
both an informant and the participant and include clinical judgment garnered through direct observation and
personal interaction with the informant and patient.

Instrument modification
Questionnaire version: CDR-QDS

Interview version: CDR-IDS

Original CDR questions were uniformly modified to ascertain degree of cognitive impairment and the extent to
which change had occurred in relation to the participant’s prior baseline. In order to effect this general
modification, in some cases, we generated qualifiers for
affirmative responses; for example, endorsement of the
CDR question “Does he/she have problems with his/her
memory or thinking?” triggered a new follow-up question: “Did he/she ALWAYS have a problem with his/her
memory or thinking?” (Yes (1)/No (0)). If the DS adult
was reported to currently have problems with memory
or thinking (current score = 1) but he/she always had
this problem (always score = 1), then the CDR-DS rating
for cognitive decline was calculated to be zero (current
score 1–always score 1 = 0).
In other cases, items related to the DS adult’s current
level of functioning were paired with identical companion
items eliciting an endorsement of the same item with respect to his/her best ever level of functioning; for example, the CDR question “How often does he/she know
the exact day of the month?” has response categories:
Usually (0), Sometimes (1), Rarely (2), and Don’t Know.
If the DS adult was reported to currently Rarely know
the exact day of the month but his/her best ever ability
was that he/she Sometimes knew the exact day of the

Examination of CDR-QDS data prompted modifications
that were included in the CDR-IDS. In addition, unlike
the CDR-QDS where a cognitive decline score was generated for every item, CDR-IDS scoring included clinical
judgment as well as direct assessment of the DS adult.
Two members of the team (CNLS and OLDR) underwent
CDR clinical training through the Knight Alzheimer Disease Research Center at Washington University. One
member (OLDR) performed the face-to-face interviews
with the informant and the DS adult and the other
reviewed the video recordings of the interviews. We each
scored the interviews separately and together reached a
consensus on disparate scores by discussing rationales for
the original scores. Consistent with CDR scoring [22],
each cognitive domain was given a score of 0 (typical), and
0.5, 1, 2, or 3 reflecting very mild, mild, moderate, or severe dementia respectively. A sum of boxes CDR-IDS
score was generated by summing across cognitive domain
scores as well as a global CDR-IDS score generated using
published rules that weighted the memory domain score
more heavily than other domains [22]. The extended
number of modified questions in the CDR-IDS along with
the difference in the scoring process allowed us to generate scores that reflected no adjustment (i.e., current
scores) or adjustment for premorbid ability.
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Statistical analysis

Data were managed using REDCap electronic data
capture tools [32] hosted by the Washington University School of Medicine. REDCap (Research Electronic
Data Capture) is a secure, web-based application designed to support data capture for research studies,
providing (1) an intuitive interface for validated data
entry; (2) audit trails for tracking data manipulation
and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data
from external sources. Similarity in cognitive decline
scores across cognitive domains and across modified
questionnaire and interview instruments was estimated using Spearman rank order correlation. Spearman correlation was also used to examine the
association of cognitive decline scores with age and
IQ. Inter-rater reliability in scoring of the modified
CDR-IDS interview was estimated using the kappa coefficient [33].

Results
Sample characteristics

Of the 40 returned CDR-QDS questionnaires, 6 were
incomplete due to missing data. For the remaining 34
completed questionnaires (2 DS adults were nonverbal), mean age of the DS adults was 33.2 years old
(SD = 9.7; range 18–55 years), 15 were women
(44.1%), 30 DS adults lived with the responder
(88.2%), and the responder was the mother for 28 of
the DS adults (82.4%), with the father and full sibling
reporting on 4 and 2 of the DS adults, respectively
(11.8% and 5.9%). Respondents reported spending an
average of 55.5 h per week with the DS adult (SD =
29.5, range 4–112 h).
Thirty-three of the 34 families with CDR-QDS data
were invited to come to the laboratory. From these 33
families, 22 completed assessments in the laboratory.
Of the 11 families who did not come to the laboratory,
5 declined to participate, 4 withdrew from the study
after initially agreeing to participate, and 2 families did
not respond to repeated calls. Five of the 9 families
who declined to participate or withdrew from the study
had reported relatively high CDR-QDS scores for the
DS adult (≥ 14 where the scoring range was 0–32). The
22 participant families comprised 10 women with DS
(45.5%), all non-Hispanic White, of average age 32.8
(SD = 8.9, range 20–56 years) and average IQ of 59 (SD
= 19.5, range 24–85; IQ was not computed for two individuals who were not able to complete Raven’s task,
one of whom was nonverbal).
History of medical and behavioral problems was obtained from the differential diagnosis screening questions of the DSDS [15]. Of the 22 DS adults, 16 (72.7%)
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had hypothyroidism; 9 (40.9%) had hearing/ear problems; 5 (22.7%) had vision problems; 5 had heart problems; 6 (27.3%) had sleep apnea; 5 had depression,
anxiety, or mood problems; 2 (9.1%) had suicidal ideation; 11 (50%) had obsessive-compulsive disorder; and 2
had aggressive behavior including verbal aggression.
There was 80% power to detect a correlation coefficient ≥ |0.44| (2-tailed alpha) with n = 34 and a coefficient ≥ |0.53| (2-tailed alpha) with n = 22.
CDR-IDS inter-rater reliability

Table 1 shows that inter-rater reliability was very high
for CDR-IDS cognitive domain and global scores adjusted for premorbid function (kappas = 0.82 to 1).
Inter-rater reliability was overall high for unadjusted
CDR-IDS scores (kappas = 0.79 to 1) with the weakest reliability (kappa = 0.55) for the judgment and
problem solving cognitive domain.
Distribution of CDR-QDS and CDR-IDS scores

Figure 1 shows the distribution of summary CDRQDS scores (n = 34); the sample manifested a wide
range of scores. The distribution was skewed toward
lower scores where 13 individuals had a score of 0
(38.2%), and another 10 individuals had scores of 1
or 2 (29.4%). CDR-QDS summary score mean was
4.85 (SD = 7.29, median = 1, range 0–23, maximum
possible score = 32). There were three individuals
with CDR-QDS scores ≥ 20, all of whom were over
the age of 30 years.
Figure 2 shows the distribution of CDR-IDS sum
of boxes (upper panel), global (middle panel), and
dichotomized global scores (lower panel) (n = 22)
when scores were adjusted for premorbid function
(adjusted) and not adjusted (unadjusted), which
would be consistent with current function. As predicted, adjusting for premorbid ability shifted, in the
non-pathological direction, scores that would otherwise be elevated on the standard version of the
Table 1 Inter-rater reliability for CDR-IDS scores before
(unadjusted) and after (adjusted) accounting for premorbid
function
CDR-IDS domain and global
scores n = 22

Unadjusted

Adjusted

Kappa

SE

Kappa

SE

Memory

0.79

0.11

0.91

0.08

Orientation

0.94

0.06

1.00

0.00

Judgment and problem solving

0.55

0.13

0.82

0.15

Community affairs

0.92

0.08

1.00

0.00

Home and hobbies

1.00

0.00

1.00

0.00

Personal care

0.86

0.09

1.00

0.00

CDR-IDS global score

0.92

0.08

0.92

0.08
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Fig. 1 Frequency distribution of summary scores of the CDR questionnaire for Down syndrome (CDR-QDS)

CDR. CDR-IDS adjusted sum of boxes sample mean
was 1.68 (SD = 3.90, median = 0.5, range 0–16,
maximum possible score = 18) and unadjusted mean
was 4.41 (SD = 3.88, median = 3, range 0.5–16). The
table embedded in the middle panel of Fig. 2 shows the
extent to which adjustment for premorbid ability shifted
individuals to lower global CDR-IDS scores. For example,
of the 13 DS adults with adjusted global CDR-IDS scores
of 0, 10 had unadjusted scores of 0.5. The shift from any
severity of dementia (CDR-IDS > 0) to no dementia
(CDR-IDS = 0) is most pronounced in the lower panel,
where nearly the entire sample (21 of 22 DS adults) meets
criteria for at least very mild dementia before score adjustment, but only 9 individuals meet the dichotomized dementia threshold after score adjustment.

Relationship of age and IQ to CDR-QDS and CDR-IDS

Table 2 shows that older age was significantly related to greater decline in all CDR-QDS cognitive
domains, except for memory and total score. When
individuals with zero scores were excluded from correlation estimation, older age was significantly related to both memory decline (Spearman rho = 0.49,
p < 0.05, n = 17) and to total CDR-QDS score (rho
= 0.41, p < 0.05, n = 21).
Older age was not significantly related to CDR-IDS
domain, sum of boxes, or global decline scores. Excluding individuals with zero scores resulted in stronger relationships between older age and decline in
memory (rho = 0.62, p = 0.14, n = 7), home and hobbies (rho = 0.50, p = 0.31, n = 6), CDR-IDS sum of
boxes (rho = 0.32, p = 0.31, n = 12), and CDR-IDS
global score (rho = 0.83, p < 0.05, n = 9). The sample
size was n = 2 to 4 for the remaining four domains.

Higher IQ was related to lower (better) cognitive
function scores overall for both the CDR-QDS and
CDR-IDS instruments with correlations (rho > − 0.45)
reaching statistical significance.
Relationship between CDR-QDS, CDR-IDS, and DSDS

Table 3 shows that decline in any one domain was significantly associated with decline in other domains and
in summary scores within instrument (upper two panels)
and across instruments (lower panel). The strongest relationship between the CDR-QDS and CDR-IDS was in
the domain for personal care (rho = 0.87) and the weakest relationship was for judgment and decision-making
(rho = 0.44) and orientation (rho = 0.45). There was a
high correspondence between the CDR-QDS summary
score and the CDR-IDS sum of boxes score (rho = 0.69).
DSDS ratings resulted in 20 of 22 individuals having
no dementia (data not shown). One person had a DSDS
cognitive cutoff score of 2, a threshold for which 6month reassessment is recommended [15]. One person
had a DSDS rating consistent with early dementia (cognitive cutoff score ≥ 3 and total early and middle stage
items present ≥ 10 but < 17). These two DS adults had,
respectively, high summary CDR-QDS scores of 17 and
10, high CDR-IDS sum of boxes of 10.5 and 16, and the
two highest global CDR-IDS scores of 2 and 3. Among
the 20 DS adults rated as having no dementia according
to the DSDS, 8 individuals had non-zero CDR-QDS
scores (range 1–8) and 7 individuals had non-zero adjusted CDR-IDS global scores (0.5 and 1).

Discussion
The modified CDR-QDS and CDR-IDS instruments captured a range of cognitive decline, provided complementary
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Fig. 2 Frequency distributions of the CDR interview for Down syndrome (CDR-IDS) sum of boxes (upper panel), global scores (middle panel), and
dichotomized global scores (lower panel). Score distributions are shown before and after adjustment for premorbid ability. The table embedded
in the middle panel illustrates the shift of individuals from higher unadjusted to lower adjusted global scores

information and exhibited moderate to strong intercorrelations for the critical domains.
Our approach to account for premorbid function is
similar to that of the CAMDEX-DS interview and
DSQIID questionnaire. In the CAMDEX-DS, endorsement of functional difficulty is followed by a question of

whether the difficulties represent deterioration [20]. In
the DSQIID, accounting for premorbid function is implicit in the response options of individual items, which include the following: always been the case, always but
worse, new symptom in past year, and does not apply
[12]. The recommended cutoff score for the DSQIID is
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Table 2 Spearman correlations of cognitive domains and summary scores with age and IQ
Domains and summary scores

CDR-QDS (n = 34)

Memory

CDR-IDS (n = 22)

Age

IQ (n = 20)

Age

IQ (n = 20)

0.11

− 0.35

0.21

− 0.32

Orientation

0.37

− 0.47

0.13

− 0.27

Judgment and problem solving

0.40

− 0.42

0.31

− 0.36

Community affairs

0.35

− 0.62

0.38

− 0.30

Home and hobbies

0.36

− 0.49

0.13

− 0.41

Personal care

0.37

− 0.49

0.39

− 0.54

CDR-QDS summary/CDR-IDS sum of boxes

0.11

− 0.45

0.16

− 0.52

CDR-IDS global score

n/a

0.10

− 0.46

Statistically significant correlations (p < 0.05) are in italics

≥ 20 for best sensitivity and specificity of the English
version [12], and ≥ 22 for the Chinese version [21]. It
was not possible to establish cutoff scores for the CDRQDS because of our limited sample size.
In our study, accounting for premorbid abilities dramatically shifted the score distribution toward lower (no
dementia) scores, which clearly demonstrates how not

accounting for premorbid abilities would result in a high
false positive rate of cognitive impairment. CDR scoring
for the typical population emphasizes memory domain
scores [22]. This emphasis was not uniformly seen in
our sample. For example, unadjusted CDR-IDS scores
showed that of 8 DS adults whose unadjusted memory
domain scores were zero, 6 individuals had scores on

Table 3 Spearman correlations across cognitive domains and summary scores within and between instruments
CDR-QDS (n = 34)

Memory

Orientation

Judgment

Community affairs

Home and hobbies

Personal care

Orientation

0.68

Judgment and problem solving

0.69

0.85

Community affairs

0.65

0.80

0.87

Home and hobbies

0.65

0.62

0.85

0.81

Personal care

0.69

0.68

0.90

0.87

1.00

Summary score

0.91

0.70

0.81

0.80

0.75

0.77

Memory

Orientation

Judgment

Community affairs

Home and hobbies

Personal care

CDR-IDS (n = 22)

Summary score

Sum of boxes

Orientation

0.45

Judgment and problem solving

0.54

0.59

Community affairs

0.60

0.84

0.74

Home and hobbies

0.43

0.48

0.39

0.64

Personal care

0.58

0.59

0.50

0.74

0.62

Sum of boxes

0.77

0.50

0.57

0.53

0.71

0.70

Global score

0.87

0.60

0.48

0.57

0.47

0.72

0.87

Memory

Orientation

Judgment

Community affairs

Home and hobbies

Personal care

Summary score

Memory

0.66

0.62

0.48

0.60

0.45

0.43

0.51

Orientation

0.70

0.45

0.53

0.48

0.68

0.66

0.60

CDR-IDS

CDR-QDS

Judgment and problem solving

0.53

0.35

0.44

0.40

0.59

0.57

0.41

Community affairs

0.60

0.65

0.68

0.63

0.83

0.81

0.54

Home and hobbies

0.42

0.66

0.92

0.73

0.75

0.74

0.66

Personal care

0.52

0.35

0.66

0.63

0.87

0.87

0.63

Sum of boxes

0.61

0.51

0.69

0.54

0.61

0.61

0.69

Global score

0.69

0.48

0.53

0.51

0.60

0.59

0.66

Statistically significant correlations (p < 0.05) are in italics
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other domains that suggested mild to severe dementia.
CDR-IDS unadjusted scores across domains could include the entire scoring range from zero (no dementia)
to three (severe dementia) for an individual. Such discrepancy in score magnitude across cognitive domains is
not seen in typical aging adults (Dr. John Morris, personal communication, March 2018), and underscores
both the wide individual variability in cognitive function
in DS adults [34] and the importance of accounting for
premorbid ability in dementia assessment. Adjusted
CDR-IDS domain scores did not differ by more than one
scoring category for any individual. It has been suggested
that memory impairment may not be an early behavioral
indicator of dementia in the DS population, rather emotional and behavioral problems (e.g., apathy, increased
irritability, increased aggression, decreased interest in social interaction) and executive dysfunction (e.g., attention, planning) may be earlier symptoms of dementia in
the DS population [12, 35–37], although these must be
differentiated from treatable neuropsychiatric comorbidities in clinical practice. It has also been argued that
memory problems have a similar time course of deterioration in DS as in the typical aging population. Administration of a cognitive battery to nearly 300 DS
individuals aged 16 years and older showed that changes
in performance in visuospatial associate memory, handeye coordination, and semantic verbal fluency preceded
other cognitive changes, implicating these cognitive domains as early, prodromal behavioral markers of cognitive deterioration in DS [38]. In addition, change in tasks
directly administered to DS individuals was seen earlier than change based on informant report, suggesting
that the latter may not be sufficiently sensitive to detect early cognitive decline [38]. Similarly, the modified CDR-QDS and CDR-IDS instruments, entirely or
mostly informant-based, may not be sensitive to detect subtle, early changes of cognitive decline, including memory problems.
Higher IQ was related to lower levels of cognitive decline. In the typically developing aging population,
greater “cognitive reserve,” a measure that combines IQ,
education, and lifelong engagement in cognitive activities
[39], is also related to lower cognitive decline [40]. Here,
we show a relationship in the lower distribution of IQ
scores assessed using a single task.
Inclusion of the DSDS was meant to serve as an external
validity index, but our sample did not reveal sufficient variability in DSDS scoring, and it is notable that a wider range
of scores were elicited among the subjects using the CDR instruments. The vast majority of the sample was rated as having no dementia on the DSDS, but most had non-zero CDRQDS and CDR-IDS scores; the 2 individuals flagged for reassessment or rated as early dementia on the DSDS had
higher CDR-QDS scores, as well as CDR-IDS adjusted global
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scores consistent with moderate and severe dementia. The
DSDS was developed and validated in a community sample
of individuals the majority of whom had severe to profound
intellectual disability which could result in low sensitivity of
the DSDS in detecting dementia in higher functioning individuals [16, 17]. We note that in another instrument, the
DSQIID, has been adapted by the National Task Group
(NTG) on Intellectual Disabilities and Dementia Practices as
an Early Detection Screen for Dementia (NTG-EDSD [41]),
for wide use in dementia screening. Our results using comparable methods in the questionnaire version of the CDR
support the utility of questionnaire-based screening, and future studies should continue to explore the utility of combining caregiver screening and direct observation in identifying
dementia in DS and distinguishing it from other neuropsychiatric impairments that can result in cognitive decline
in DS, most notably, catatonia, which is rare and controversial, but is treatable [42] and may assist clinicians in avoiding
a false designation of dementia on the basis of observations
or ratings that suggest cognitive decline, especially in younger
adults with DS.
The participant interview portion of the CDR-IDS was
difficult to administer to DS adults who were nonverbal
or whose speech was limited or difficult to understand.
The original CDR was developed for the typical population and in more extreme cases, it cannot capture the
full range of disability. Ability to capture cognitive decline across the range of premorbid impairment in DS
individuals, from low to high functioning, with a single
instrument is a challenge [43]. In the CDR, “thinking
and memory problems” are considered interchangeably,
but caregiver informants regarded “thinking” and “memory” to be different phenomena and were often unsure
how to answer questions that asked about thinking and
memory problems together. Some spatial orientation
questions were difficult because DS participants in our
study were never alone and informants could not evaluate whether the DS adult would be able to find his/her
way around familiar streets, for example. Ability to manage a household emergency like a small leak or fire did
not seem applicable in our sample, again, since DS
adults were almost never alone—even those who live independently have scheduled visitors and structured days.
Ability to drive a vehicle or do calculations was absent
in our entire sample.
Based on our data and on personal interaction with
DS adults and their family members, ongoing research
should continue to focus on elements of caregiver report
and direct assessment of the DS individual that will
optimize differential diagnosis. The primary goal of this
study was to adapt the widely used CDR for assessment
of dementia in adults with DS. We have shown that such
adaptation was successful in capturing a range of cognitive decline and in shifting the distribution of decline
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scores toward lower/no impairment by adjusting original
CDR questions to take into account premorbid intellectual and functional ability. Future work of the CDR-QDS
and CDR-IDS should include comparison with existing
instruments such as the CAMDEX-DS and DSQIID,
with neuropsychological performance, and with other
biomarkers, such as positron emission tomography for
amyloid or tau.

Conclusions
The modified CDR questionnaire (CDR-QDS) and interview (CDR-IDS) instruments capture a range of impairment in DS adults. Adjustment of cognitive decline
scores for premorbid function dramatically shifted the
score distribution toward no/low impairment and was
an important element in identifying DS adults with suspicion for dementia. The DSDS indicated high suspicion
of dementia in two of twenty-two individuals in this
sample who had broadly elevated scores on the modified
CDR instruments. The modified CDR instruments captured a range of subthreshold impairments in cognitive
function that may prove extremely useful in prospective
studies of the development of AD in DS. Moreover, future research is warranted to use quantitative scales such
as these to help differentiate dementia from other neuropsychiatric problems in DS, including catatonia, adjustment disorder, and a range of psychiatric comorbidities,
all of which are potentially treatable and for which inappropriate/premature assignment of a diagnosis of dementia may be extremely misleading and result in a
major obstacle to appropriate care and treatment. For
DS adults with elevated scores for cognitive impairment
in this study, the impairment generally encompassed
multiple cognitive domains and was not predominantly
within the memory domain, as seen in the typical
population.
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